JP2022525202A - 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 - Google Patents

肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 Download PDF

Info

Publication number
JP2022525202A
JP2022525202A JP2021555469A JP2021555469A JP2022525202A JP 2022525202 A JP2022525202 A JP 2022525202A JP 2021555469 A JP2021555469 A JP 2021555469A JP 2021555469 A JP2021555469 A JP 2021555469A JP 2022525202 A JP2022525202 A JP 2022525202A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
diazaspiro
decane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525202A5 (https=
JPWO2020188352A5 (https=
Inventor
マグダレーナ アロンソ－ガリシア，
デイビッド カーペンター，
トーマス パック，
メリッサ ローズ，
ジュリー ルーカ，
スティーブ リング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of JP2022525202A publication Critical patent/JP2022525202A/ja
Publication of JP2022525202A5 publication Critical patent/JP2022525202A5/ja
Publication of JPWO2020188352A5 publication Critical patent/JPWO2020188352A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021555469A 2019-03-15 2020-03-13 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 Pending JP2022525202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819162P 2019-03-15 2019-03-15
US62/819,162 2019-03-15
PCT/IB2020/000177 WO2020188352A1 (en) 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Publications (3)

Publication Number Publication Date
JP2022525202A true JP2022525202A (ja) 2022-05-11
JP2022525202A5 JP2022525202A5 (https=) 2023-02-13
JPWO2020188352A5 JPWO2020188352A5 (https=) 2023-02-13

Family

ID=71092560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555469A Pending JP2022525202A (ja) 2019-03-15 2020-03-13 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量

Country Status (9)

Country Link
US (2) US11576915B2 (https=)
EP (1) EP3938043A1 (https=)
JP (1) JP2022525202A (https=)
KR (1) KR20210139293A (https=)
CN (1) CN113784717A (https=)
AU (1) AU2020244278A1 (https=)
CA (1) CA3133589A1 (https=)
MX (1) MX2021011224A (https=)
WO (1) WO2020188352A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US11607413B2 (en) * 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530299A (ja) * 2013-09-06 2016-09-29 カロス・ファーマシューティカルズ・インコーポレイテッドＫａｒｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) * 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530299A (ja) * 2013-09-06 2016-09-29 カロス・ファーマシューティカルズ・インコーポレイテッドＫａｒｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. Vol.195, 195:A4193, JPN6023052725, 2017, ISSN: 0005374000 *
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 360, no. 2, JPN6023052724, 2017, pages 267 - 279, ISSN: 0005373999 *
薬剤学, vol. 68, no. 5, JPN6022055481, 2008, pages 344 - 349, ISSN: 0005374001 *

Also Published As

Publication number Publication date
US11576915B2 (en) 2023-02-14
US20200289510A1 (en) 2020-09-17
AU2020244278A1 (en) 2021-09-30
KR20210139293A (ko) 2021-11-22
EP3938043A1 (en) 2022-01-19
US20240024316A1 (en) 2024-01-25
WO2020188352A1 (en) 2020-09-24
CN113784717A (zh) 2021-12-10
CA3133589A1 (en) 2020-09-24
MX2021011224A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US7834056B2 (en) Pharmaceutical composition for gout
JP2022525202A (ja) 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
KR100404303B1 (ko) 올티프라즈의 간섬유화 및 간경화 진행의 예방 및치료제로서의 용도 및 올티프라즈를 주성분으로 함유하는제약 조성물
TW202034921A (zh) 癌症療法
CA3157656A1 (fr) Utilisation de nictotinamide mononucleotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoide et compositions correspondantes
JP7591283B2 (ja) ブドウ膜黒色腫の治療のための併用療法
KR20250005055A (ko) 아스피린 및 기타 nsaid의 고 침투성 전구약물을 이용한 심혈관 질환의 예방 또는 치료
WO2023192372A1 (en) Methods of treating sjögren-larssen syndrome
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
RU2412701C2 (ru) Способ снижения непереносимости противотуберкулезных препаратов
HK40058221A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
BE829197A (fr) Compositions anti-inflammatoires, leur preparation et leur utilisation
TW202214249A (zh) 紫質症之預防或治療劑
HK40061016A (en) Combination therapy for the treatment of uveal melanoma
EP1465633A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
JPH078791B2 (ja) ジベンズ〔ｃｄ，ｆ〕インド−ルの新規用途
WO2004105753A1 (ja) 抗うつ剤または抗うつ用飲食品

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240723